TOP TIERMARKET NEWSWIRE

News & sentiment

BELITE BIO INC ADR (BLTE) — News & AI sentiment

BELITE BIO INC ADR (BLTE) news roundup. 6 stories in the past week, 19 over 30 days. Average 30-day sentiment is 59.8/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 6 sales totalling $34.9M — net selling of $34.9M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

6

avg sentiment 62.2/100

30d stories

19

avg sentiment 59.8/100

Insider net (90d)

$34.9M

0 buys · 6 sells

Congress (90d)

0

0 buys · 0 sells

BLTE news in the last 24 hours, 7 days, 30 days and 90 days

How much BLTE coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	BLTE stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	6	62.2/100	BLTE headlines →
Last 30 days	19	59.8/100	BLTE headlines →
Last 90 days	39	60.3/100	BLTE headlines →

Latest stories on BLTE

Mizuho raises Belite Bio stock price target on Japan drug filing

Investing.com Analyst Ratings63 · neutralanalyst

4d ago

Belite Bio price target raised to $234 from $220 at Mizuho

The Fly61 · neutralanalyst

4d ago

Belite Bio On Track For A Potential Blockbuster Launch In 2027

Seeking Alpha56 · neutralproduct/pr

4d ago

Belite Bio price target raised to $245 from $214 at H.C. Wainwright

The Fly63 · neutralanalyst

5d ago

Belite Bio submits NDA to MHLW in Japan for tinlarebant in STGD1

The Fly63 · neutralproduct/pr

5d ago

Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1

GlobeNewswire67 · bullishproduct/pr

5d ago

Canaccord initiates Belite Bio stock with buy on Stargardt therapy

Investing.com Analyst Ratings61 · neutralanalyst

Sep 4

Canaccord starts Belite Bio at Buy on additional post-IPO upside

The Fly61 · neutralanalyst

Sep 4

Belite Bio initiated with a Buy at Canaccord

The Fly61 · neutralanalyst

Sep 4

H.C. Wainwright reiterates Belite Bio stock rating on commercial plans

Investing.com Analyst Ratings56 · neutralanalyst

Sep 3

Belite Bio, Inc (BLTE) Discusses Prelaunch Strategy and Commercial Opportunity for Tinlarebant in Stargardt Disease Type 1 Transcript

Seeking Alpha56 · neutralproduct/pr

Sep 2

Belite Bio to Participate in Four Upcoming Investor Conferences

GlobeNewswire55 · neutralgeneral

Sep 1

Belite Bio to Host Virtual Commercial Day on September 2, 2026

StockTitan67 · bullishproduct/pr

Aug 24

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

StockTitan56 · neutralproduct/pr

Aug 21

Belite Bio price target raised to $206 from $201 at Morgan Stanley

The Fly61 · neutralanalyst

Aug 17

Belite Bio reports Q2 EPS (54c), consensus (78c)

The Fly34 · bearishearnings

Aug 17

Belite Bio price target raised to $220 from $215 at Mizuho

The Fly61 · neutralanalyst

Aug 16

Belite Bio price target raised to $270 from $266 at Cantor Fitzgerald

The Fly61 · neutralanalyst

Aug 16

Benchmark reiterates Belite Bio stock rating on FDA priority review

Investing.com Analyst Ratings56 · neutralanalyst

Aug 14

Belite Bio outlines February 12, 2027 PDUFA date for Tinlarebant in Stargardt disease following FDA priority review acceptance

Seeking Alpha73 · bullishproduct/pr

Aug 13

Belite Bio, Inc (BLTE) Q2 2026 Earnings Call Transcript

Seeking Alpha50 · neutralearnings

Aug 13

Belite Bio Q2 Earnings Call Highlights

Yahoo Top73 · bullishproduct/pr

Aug 13

Belite Bio reports Q2 results

Seeking Alpha34 · bearishearnings

Aug 13

Belite Bio Gains FDA Priority Review for Tinlarebant as Losses Widen on Commercial Build-Out

TipRanks58 · neutralproduct/pr

Aug 13

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

GlobeNewswire50 · neutralearnings

Aug 13

Open BLTE in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →